Clinical trials
Antisynthetase Syndrome clinical trials
Below are recruiting antisynthetase syndrome clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07406932Recruiting
JAK inhibitors vs standard therapy for lung scarring in Anti-Synthetase Syndrome
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Beijing, Beijing MunicipalityAges 18–75 - NCT06613490RecruitingEarly Phase 1
CAR NK cells for antibody syndrome and rheumatoid arthritis
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
Nanjing, JiangsuAges 18–70 - NCT05984394Recruiting
Study of immune cells in new antisynthetase syndrome with lung disease
This study looks at special immune cells (T cells) in people newly diagnosed with antisynthetase syndrome that has affected their lungs. It aims to understand how these cells are involved in the condition, which could lead to better treatments.
DijonAges 18 years+ - NCT07391605RecruitingPhase 2
Descartes-08 for treatment-resistant myositis
This trial tests a new treatment called Descartes-08 for people with dermatomyositis or antisynthetase syndrome whose disease hasn't responded well to standard therapies. It aims to see if this treatment can help control muscle and skin symptoms.
Orange, CaliforniaAges 18 years+ - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+
Hear when a new Antisynthetase Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antisynthetase syndrome?
- Yes. Clin2 currently lists 5 recruiting antisynthetase syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antisynthetase syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antisynthetase syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.